These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 21828346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP, Markova AA, Calle Serrano B, Cornberg M.
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 investigators.
    Lancet; 2010 Aug 28; 376(9742):705-16. PubMed ID: 20692693
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Aug 28; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 8. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M, Silva M, Spooner L, Comee MK, Malloy M.
    Clin Ther; 2013 Feb 28; 35(2):190-7. PubMed ID: 23369368
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [New agents for the treatment of hepatitis C].
    Buti M, Homs M.
    Enferm Infecc Microbiol Clin; 2012 Mar 28; 30(3):147-50. PubMed ID: 22118805
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.
    Hepatology; 2012 Aug 28; 56(2):567-75. PubMed ID: 22619063
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM, Heil EL.
    Ann Pharmacother; 2013 Feb 28; 47(2):228-36. PubMed ID: 23386076
    [Abstract] [Full Text] [Related]

  • 17. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.
    Antivir Ther; 2011 Feb 28; 16(5):695-704. PubMed ID: 21817191
    [Abstract] [Full Text] [Related]

  • 18. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ.
    J Clin Gastroenterol; 2014 Feb 28; 48(5):435-43. PubMed ID: 24177376
    [Abstract] [Full Text] [Related]

  • 19. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1207-17. PubMed ID: 21449784
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.